Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

Trial ID or NCT#

NCT00185809

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to examine breast cancers that express the protein (NIS) that may be found in malignant breast tissues and to evaluate proteins found in blood and their relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly treat some breast cancers with radioactive iodine, and to calculate the amount of radioactive iodine entering breast cancer cells, how long your cancer retains the agent as well as how much is taken up by other organs, particularly the thyroid gland.

Official Title

Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

Eligibility Criteria

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Only women diagnosed with breast cancer - 18 years of age or older - From whom informed consent can be obtained - Patient is able to provide a fluid (e.g. cyst fluid) - Patient with blood test that shows protein may allow iodide to accumulate in breast tissue - Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours
Exclusion Criteria:
  1. - Males - Children
View All Criteria
Show Less

Investigator(s)

Irene Wapnir, MD
Irene Wapnir, MD
Surgical oncologist, Breast surgeon, Breast specialist
Professor of Surgery (General Surgery)
Sanjiv Sam Gambhir, MD, PhD
Michael L. Goris

Contact us to find out if this trial is right for you.

Contact

Marilyn Florero
6507241953

View on ClinicalTrials.gov